Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 13/20 | 0.73 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | OXTR | P30559 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420499 | 0.86 | APLNR (0.67) | APLNRTSHRKDM4E | |
| SCHEMBL18245535 | 0.85 | APLNR (1.00) | APLNR | |
| SCHEMBL20180776 | 0.84 | AVPR1A (0.68) | APLNRAVPR2AVPR1AOXTR | |
| SCHEMBL22518538 | 0.82 | APLNR (0.63) | APLNRAVPR2AVPR1A | |
| SCHEMBL20207290 | 0.82 | APLNR (0.73) | APLNR | |
| SCHEMBL18247041 | 0.82 | APLNR (0.73) | APLNRAVPR2AVPR1A | |
| SCHEMBL20515259 | 0.82 | AVPR2 (0.54) | APLNRAVPR2AVPR1ATSHROXTR | |
| SCHEMBL18246225 | 0.81 | APLNR (0.71) | APLNR | |
| SCHEMBL20167443 | 0.80 | APLNR (0.61) | APLNR | |
| SCHEMBL18246411 | 0.80 | APLNR (1.00) | APLNRTSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3541810-B1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3541810-B1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20190284173-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284173-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-19 | — | — | US | disclosed |
| WO-2018093579-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284173-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, TBXA2R | APLNR 4/4885AVPR2 119/4885AVPR1A 194/4885 |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | APLNR 4/4885AVPR2 119/4885AVPR1A 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.